2. Search Result
Search Result
Results for "

ABCA1

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

7

Natural
Products

1

Recombinant Proteins

3

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0388
    Probucol
    2 Publications Verification

    DH-581

    		 Virus Protease Apoptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Caspase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases [1] .
    Probucol
  • HY-D0086
    DIDS sodium salt
    20+ Cited Publications

    MDL101114ZA

    		 VDAC RAD51 Cancer
    DIDS sodium salt (MDL101114ZA) is a dual inhibitor of ABCA1 and VDAC1. DIDS also inhibits RAD51, inhibiting RAD51-mediated homologous pairing and strand exchange reactions. DIDS inhibits anion exchange and binding to red blood cell membranes, inhibits the activation of caspase-3 and -9, and can be used in cancer research [1] .
    DIDS sodium salt
  • HY-173230
    ABCA1 inducer 2

    		ATP-binding cassette (ABC) transporters LXR Cardiovascular Disease
    ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential [1].
    ABCA1 inducer 2
  • HY-P6306
    CS-6253
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease [1] .
    CS-6253
  • HY-W020012
    Fluoresterol

    22-NBD Cholesterol

    		 Fluorescent Dye Metabolic Disease
    Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) [1] .
    Fluoresterol
  • HY-18282
    AZ876

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis [1] .
    AZ876
  • HY-143200
    OSBPL7-IN-1
    1 Publications Verification

    		 Apolipoprotein Oxysterol-binding Protein-related Protein (ORP) Metabolic Disease
    OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression [1].
    OSBPL7-IN-1
  • HY-N0364
    Falcarindiol
    3 Publications Verification

    		 Apoptosis Autophagy PPAR Infection Metabolic Disease Inflammation/Immunology Cancer
    Falcarindiol, an orally active polyacetylenic oxylipin, activates PPARγ and increases the expression of the cholesterol transporter ABCA1 in cells. Falcarindiol induces apoptosis and autophagy. Falcarindiol has anti-inflammatory, antifungal, anticancer and antidiabetic properties [1] . Falcarindiol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Falcarindiol
  • HY-N2419
    Erythrodiol
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Erythrodiol is an olive oil component. Erythrodiol promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein. Erythrodiol is a good candidate to be further explored for therapeutic or preventive application in the context of atherosclerosis [1].
    Erythrodiol
  • HY-NP203
    High density lipoprotein (human)

    HDL (human)

    		 Apolipoprotein NO Synthase LPL Receptor Akt PI3K p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    High density lipoprotein (human) (HDL (human)) is a human-derived high-density lipoprotein. High density lipoprotein can cross the blood-brain barrier, and partially acts on endothelial nitric oxide synthase (eNOS) by activating surface receptors such as SR-B1 and S1P3R, as well as intracellular signaling cascades involving Akt, PI3K and MAPK, thereby inducing the production of NO in endothelial cells. High density lipoprotein (human) can be used in research related to type 2 diabetes, Alzheimer's disease, cancer and atherosclerosis [1] .
    High density lipoprotein (human)
  • HY-123148
    IMB-808

    		LXR Inflammation/Immunology
    IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used for the study of atherosclerosis research [1].
    IMB-808
  • HY-121693
    DIDS

    MDL101114ZA free base

    		 VDAC RAD51 Cancer
    DIDS is a dual inhibitor of ABCA1 and VDAC1. DIDS also inhibits RAD51, inhibiting RAD51-mediated homologous pairing and strand exchange reactions. DIDS inhibits anion exchange and binding to red blood cell membranes, inhibits the activation of caspase-3 and -9, and can be used in cancer research [1] .
    DIDS
  • HY-N0686
    Pseudoprotodioscin
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) MicroRNA Metabolic Disease
    Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides [1].
    Pseudoprotodioscin
  • HY-134377
    Bocidelpar

    ASP0367; MA-0211

    		 PPAR Metabolic Disease
    Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) [1] .
    Bocidelpar
  • HY-117006
    E1231
    1 Publications Verification

    1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one

    		 Sirtuin Cardiovascular Disease
    E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE -/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases [1].
    E1231
  • HY-141645
    IMM-H007

    WS070117

    		 AMPK TGF-β Receptor NF-κB JNK AP-1 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis [1] .
    IMM-H007
  • HY-123402
    GSK3987
    2 Publications Verification

    		 LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation [1].
    GSK3987
  • HY-RS00037
    ABCA1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    ABCA1 Human Pre-designed siRNA Set A contains three designed siRNAs for ABCA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ABCA1 Human Pre-designed siRNA Set A
    ABCA1 Human Pre-designed siRNA Set A
  • HY-169080
    ABCA1 inducer 1

    		Apolipoprotein Neurological Disease
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4 [1].
    ABCA1 inducer 1
  • HY-W674245
    10-Hydroxyhexadecanoic acid

    		ATP-binding cassette (ABC) transporters Cardiovascular Disease
    10-Hydroxyhexadecanoic acid is a hydroxy fatty acid found in Camembert cheese. 10-Hydroxyhexadecanoic acid can promote cholesterol efflux from ABCA1 and ABCG1, preventing the accumulation of excess cholesterol in cells. 10-Hydroxyhexadecanoic acid can be used in anti-atherosclerosis research [1].
    10-Hydroxyhexadecanoic acid
  • HY-P6306A
    CS-6253 TFA
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease [1] .
    CS-6253 TFA
  • HY-W201317
    E17241

    		PPAR Metabolic Disease
    E17241 is an inducer of the expression of ABCA1 that increases the protein levels of ABCA1 in RAW 264.7 macrophages. E17241 is also an agonist of peroxisome proliferator-activated receptors (PPARs ). E17241 decreases plasma glucose levels and body weight in KKAy diabetic mice fed a high-fat and high-glucose (HFHG) diet [1] .
    E17241
  • HY-RS22987
    Abca1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Abca1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Abca1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Abca1 Rat Pre-designed siRNA Set A
    Abca1 Rat Pre-designed siRNA Set A
  • HY-W590664
    C2 Dihydroceramide

    		Endogenous Metabolite Cardiovascular Disease
    C2 Dihydroceramide is a derivative of C2 Ceramide (HY-101180). C2 Dihydroceramide enhances the ABCA1-mediated cholesterol efflux to apolipoprotein A-I (apoA-I) without causing cytotoxicity [1].
    C2 Dihydroceramide
  • HY-181520
    ABCA1 inducer 3

    		ATP-binding cassette (ABC) transporters Metabolic Disease
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia [1].
    ABCA1 inducer 3
  • HY-RS16554
    Abca1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Abca1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abca1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Abca1 Mouse Pre-designed siRNA Set A
    Abca1 Mouse Pre-designed siRNA Set A
  • HY-170570
    PFM046

    		LXR Stearoyl-CoA Desaturase (SCD) Fatty Acid Synthase (FASN) Cancer
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models [1].
    PFM046
  • HY-122936
    Tanshindiol C

    		Histone Methyltransferase Keap1-Nrf2 Sirtuin Cardiovascular Disease Cancer
    Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC50 of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research [1] .
    Tanshindiol C
  • HY-185104
    Ginsenoside C-K hexapropionate ester

    		LXR Cardiovascular Disease
    Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride [1].
    Ginsenoside C-K hexapropionate ester
  • HY-179278
    LXR agonist 4

    		LXR Cardiovascular Disease Metabolic Disease Endocrinology
    LXR agonist 4 is a selective LXR inverse agonist with IC50 values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) [1].
    LXR agonist 4
  • HY-18282R
    AZ876 (Standard)

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis [1] .
    AZ876 (Standard)
  • HY-124273
    C2 L-threo Ceramide (d18:1/2:0)

    L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0); N-acetyl-L-threo-Sphingosine

    		 Endogenous Metabolite Cardiovascular Disease
    C2 L-threo Ceramide (d18:1/2:0) (L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0)) is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide. C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.
    C2 L-threo Ceramide (d18:1/2:0)
  • HY-N13361
    Elodeoidileon A

    		RAR/RXR Neurological Disease
    Elodeoidileon A is an agonist for RXRα, that interacts with RXRα-LBD protein with a dissociation constant Kd of 5.85 μM. Elodeoidileon A promotes the expression of ATP-binding cassette transporter A1 (ABCA1). Elodeoidileon A reveals the potential in Alzheimer's disease research [1].
    Elodeoidileon A
  • HY-N2419R
    Erythrodiol (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Erythrodiol (Standard) is the analytical standard of Erythrodiol. This product is intended for research and analytical applications. Erythrodiol is an olive oil component. Erythrodiol promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein. Erythrodiol is a good candidate to be further explored for therapeutic or preventive application in the context of atherosclerosis [1].
    Erythrodiol (Standard)
  • HY-121671
    TBTC

    		RAR/RXR Neurological Disease
    TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models [1].
    TBTC
  • HY-117555
    4010B-30

    		Apolipoprotein PPAR ATP-binding cassette (ABC) transporters Cardiovascular Disease
    4010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE -/- mice [1] .
    4010B-30
  • HY-115780
    E17110

    		LXR ATP-binding cassette (ABC) transporters Cardiovascular Disease
    E17110 is a liver X receptor β (LXRβ) agonist with an EC50 of 0.72 μM. E17110 can increase the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 macrophages. E17110 also reduce cellular lipid accumulation and promoted cholesterol efflux. E17110 can be used for the research of cardiovascular disease, such as atherosclerosis [1].
    E17110
  • HY-186045
    SKLB06489

    		Histone Methyltransferase Apoptosis DNA/RNA Synthesis ATP-binding cassette (ABC) transporters Cancer
    SKLB06489 is a selective and orally active inhibitor of type I PRMT enzymes, with IC50 values of 64.55 nM (PRMT1), 4.21 nM (PRMT6), and 51.27 nM (PRMT8). SKLB06489 inhibits cell proliferation, colony formation, DNA replication, and DNA damage repair in cancer cells. SKLB06489 induces G0/G1-phase cell cycle arrest and apoptosis in cancer cells. SKLB06489 enhances intracellular cholesterol efflux via ABCA1 and ABCG1 upregulation, disrupts cholesterol metabolic homeostasis, and suppresses tumor growth in subcutaneous xenograft models. SKLB06489 can be used for the research of triple-negative breast cancer (TNBC) [1].
    SKLB06489
  • HY-N0686R
    Pseudoprotodioscin (Standard)

    		Reference Standards Fatty Acid Synthase (FASN) MicroRNA Metabolic Disease
    Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides [1].
    Pseudoprotodioscin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: